Atossa Therapeutics Files Q1 2025 10-Q
Ticker: ATOS · Form: 10-Q · Filed: May 13, 2025 · CIK: 1488039
| Field | Detail |
|---|---|
| Company | Atossa Therapeutics, INC. (ATOS) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
**Atossa Therapeutics Q1 2025 10-Q filed. Financials and operations updated.**
AI Summary
Atossa Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including assets and liabilities, and provides updates on the company's operations. Specific financial figures and operational details are presented within the report.
Why It Matters
This filing provides investors with the latest financial health and operational status of Atossa Therapeutics, crucial for understanding its current standing and future prospects.
Risk Assessment
Risk Level: medium — Biotech companies like Atossa Therapeutics are inherently risky due to the high failure rate in drug development and regulatory hurdles.
Key Numbers
- 2025-03-31 — Period End Date (Financial reporting period)
- 2025-01-01 — Period Start Date (Financial reporting period)
- 2024-12-31 — Previous Year End Date (Comparative financial data)
- 2024-03-31 — Prior Year Quarter End Date (Comparative financial data)
Key Players & Entities
- ATOSSA THERAPEUTICS, INC. (company) — Filer
- 20250331 (date) — Period of Report
- 20250513 (date) — Filing Date
- SEATTLE (location) — Business Address City
- DE (location) — State of Incorporation
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the first quarter of 2025.
When was this 10-Q filed with the SEC?
The filing date was 20250513.
What is the company's primary business address?
The company's business address is 10202 5TH AVENUE NE, SUITE 200, SEATTLE, WA 98125.
What is the SIC code for Atossa Therapeutics, Inc.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Atossa Therapeutics, Inc.?
The fiscal year end is 1231.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding ATOSSA THERAPEUTICS, INC. (ATOS).